Christine Shaw, VP, Assay Development at GenMark Diagnostics, Inc. (GNMK), sold 425 shares at $19.35 ($8K) on 2021-02-23, disclosed to the SEC on 2021-02-25.
Open-market sale of $8k GNMK by VP, Assay Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $19.35 | 166 | $3K | 39.3% |
| 2 | $19.12 | 259 | $5K | 60.7% |
| Total | $19.21 avg | 425 | $8K | 100% |
| Filing → |
| GNMK | SELL | 2021-01-29 | $1K | — | Filing → |
| GNMK | SELL | 2020-12-09 | $4K | — | Filing → |
| GNMK | SELL | 2020-11-25 | $5K | — | Filing → |